The anti-CD38 mAb market is projected to experience substantial growth in the coming years owing to strong uptake of DARZALEX (along with DARZALEX FASPRO), the expected entry of subcutaneous formulation of SARCLISA in Multiple Myeloma. […]
Tag: DelveInsight Business Research
200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market
The ADC oncology market is experiencing rapid growth, attracting over 200 pharmaceutical companies vying for leadership in this innovative therapeutic space. As competition intensifies, advancements in technology and increased investment in research and development are […]
PARP Inhibitors Market to Register Immense Growth by 2034 Owing to Wider Opportunity in Multiple Indications with HRR (BRCA) Gene Mutations and Increasing Cost of Therapy of Leading PARP Inhibitors in the US
The PARP inhibitors market is anticipated to experience substantial growth in the coming years. This growth is driven by label expansion of leading PARP inhibitors in various indications, a rising number of cancer diagnoses mainly […]
CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications
The CDK4/6 inhibitors market is expected to grow significantly in the coming years. This is mainly due to the increasing incidence of HR+/HER2 breast cancer, the type for which CDK4/6 inhibitors are majorly prescribed. CDK4/6 inhibitors […]
The Positive Topline Results From Phase III Study of UCB/Biogen’s Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space
UCB and Biogen reported encouraging topline findings from the Phase III PHOENYCS GO trial, which assessed dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in individuals with moderate-to-severe SLE. The promising outcomes with dapirolizumab pegol […]
